CD19 and acute lymphoblastic leukemia: It has been demonstrated that lymphodepleting chemotherapy, which primarily aims to lower host T cells, also prolongs R/R B-ALL patients' event-free survival (EFS) time by promoting the proliferation and stability of anti-CD19-CAR-T cells [30, 31].